SCHEMBL7020503

SCHEMBL7020503

Cc1cc(C(C)N)c(C)o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.50
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
CA1 P00915 2/20 0.34
CA9 Q16790 2/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
HTT P42858 1/20 0.34
NQO1 P15559 1/20 0.33
CYP3A4 P08684 2/20 0.32
MEN1 O00255 1/20 0.32
GLA P06280 1/20 0.32
KMT2A Q03164 1/20 0.32
PDE2A O00408 1/20 0.31
GABRP O00591 2/20 0.30
GABRD O14764 2/20 0.30
GABRA1 P14867 2/20 0.30
GABRB1 P18505 2/20 0.30
GABRG2 P18507 2/20 0.30
GABRB3 P28472 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4298346 0.80 ALOX5 (0.48) ALOX5KDM4EMAPTCA1CA9
SCHEMBL11844598 0.73 ALOX5 (0.47) ALOX5KDM4EMAPTCA1CA9
SCHEMBL178515 0.73 ALOX5 (0.43) ALOX5KDM4EMAPTCA1CA9
SCHEMBL11687966 0.67 ALOX5 (0.42) ALOX5KDM4EMAPTCA1CA9
SCHEMBL13138022 0.66 ALOX5 (0.38) ALOX5KDM4EMAPTHTTCYP1A2
SCHEMBL23385545 0.66 ALOX5 (0.41) ALOX5KDM4EMAPTCA1CA9
SCHEMBL18917026 0.66 LMNA (0.41) LMNATP53HTTCYP3A4MEN1
SCHEMBL11687953 0.66 ALOX5 (0.38) ALOX5KDM4EMAPTCA1CA9
SCHEMBL6613744 0.66 ALOX5 (0.41) ALOX5KDM4EMAPTCA1CA9
SCHEMBL9493682 0.64 LMNA (0.39) LMNATP53HTTCYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed